Cannabis Science Inc (OTCMKTS:CBIS) has continued to consolidate in recent weeks and has dropped well below the $0.05 mark where the stock had shown some support in the past. Over the past several years as Marijuana stocks have heated up CBIS has been at the forefront of this incredible phenomenon trading massive volume and rising to incredible highs.
CBIS is at the right place at the right time; The MJ sector continues to grow; according to Forbes North American marijuana sales grew by an unprecedented 30% in 2016 to $6.7 billion as the legal market expands in the U.S. and Canada, according to a new report by Arcview Market Research. North American sales are projected to top $20.2 billion by 2021 assuming a compound annual growth rate of 25%. The report includes Canada for the first time as it moves towards implementing legal adult use marijuana.
According to ArcView Market Research, legal cannabis sales jumped by 17% to $5.4 billion in 2015. Now, the industry is expected to grow sales by 25%, to $6.7 billion in total U.S. revenue, in 2016. Additionally, ArcView Market Research predicts that the legal cannabis market will grow to $23.1 billion in total annual sales, by 2020.
Cannabis Science Inc (OTCMKTS:CBIS) works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.
CBIS initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Several years ago CBIS made a number of acquisitions in the cannabis sector that currently drive future growth. CBIS 2 most important drugs in development are:
The CS-S/BCC-1 drug program was launched in 2011 due to the “apparent success in 4 skin cancer patients who have self-administered cannabinoid based extracts topically to their skin cancers. These patients have experienced shrinking and apparent eradication of their skin cancer lesions.”
The drug CS-TATI-1 aims to target patients with drug-resistant HIV strains. The earliest article I could find relating to the launch of this program was in June 5, 2012, where the company loosely described a mission to “explore the commercial development of Phyto cannabinoid-based therapeutics for drug resistant HIV infection.”
Back in March CBIS commented on the recent success of GW Pharmaceuticals in their phase three testing of a CBD-based product designed to treat patients with a rare form of epilepsy.
The successful trials in Europe help pave the way for companies like Cannabis Science to move forward with their own testing in Europe and in the United States. It will also allow for a quicker regulatory process due to more research being made available for regulators and more experience with these types of treatments.
CBIS is working diligently to continue testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. On the heels of GW Pharmaceuticals’ success, the company is more confident than ever in its planned wide-scale rollout, which will include a wider array of near term clinical drug development programs in California, possibly Washington, and the Netherlands.
On September 5 CBIS along with Free Spirit Organics Native American Corporation (FSO NAC) announced significantly positive analytical lab testing reports from its San Joaquin Sovereign Tribal Free Land MBS, Industrial Hemp Project. Initial analytical reports from the first cut plants reveals that the strains being used are well within the boundaries of laws and regulations placed on industrial hemp research projects of this sort.
The lab results from the 2017 CBIS/FSO NAC MBS001 initial harvest show values of THC 0.26% and CBD at 5%. To date, there have been approximately 25-30 part-time workers hired so far, and it is expected that another 50-75 people will be hired before the harvest is completed. The harvesting process is very labor intensive and very seasonal until the staggering process has been completed for year around harvesting. At that point, the Company expects there will be constantly new jobs being created as the employment requirement will substantially increase to the number of full-time permanent staff to increase substantially living in the area to service the full 250 acres for this project and any required expansions.
Currently trading at a $107 million market valuation CBIS has little assets or revenues and rising short term debt that has resulted in dilution over the years. But CBIS is an exciting story developing in small caps; the Company is specializing in the development of cannabis-based medicines and has a number of new exciting initiatives in the booming pot sector. CBIS is one of the original pot stocks with a long history of making spectacular 2000% plus moves that knows how to get its story into the national media. CBIS is a great place to be when pot stocks heat up.